MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-06-2025
Verona Pharma plc DSO Ratio 2011-2026 | VRNA
Annual DSO Ratio Verona Pharma plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 136 | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 136 | 136 | 136 |
Quarterly DSO Ratio Verona Pharma plc
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64.2 | 56 | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 64.2 | 28.5 | 49.6 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aquestive Therapeutics
AQST
|
103 | $ 4.12 | -0.36 % | $ 441 M |  USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.32 | 3.67 % | $ 228 M |  Israel |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 23.65 | 0.08 % | $ 3.01 B | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
BioXcel Therapeutics
BTAI
|
103 | $ 1.16 | -2.12 % | $ 14.2 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 3.17 | 1.44 % | $ 6.9 B | Israel |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Catalyst Biosciences
CBIO
|
79.3 | $ 19.48 | 0.39 % | $ 1.74 B | USA |
 |
Codexis
CDXS
|
32.9 | $ 1.95 | 6.87 % | $ 170 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Cerus Corporation
CERS
|
47 | $ 1.91 | 2.69 % | $ 364 M | USA |
 |
Coherus BioSciences
CHRS
|
559 | $ 1.72 | -0.87 % | $ 201 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
9.68 | $ 0.46 | -13.02 % | $ 5.27 M | Israel |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Catalyst Pharmaceuticals
CPRX
|
59.5 | $ 24.95 | 1.05 % | $ 3.05 B | USA |
 |
Celldex Therapeutics
CLDX
|
321 | $ 31.33 | 0.85 % | $ 2.08 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
239 | $ 10.27 | 0.98 % | $ 137 M | USA |
 |
Cardiff Oncology
CRDF
|
294 | $ 1.6 | 1.27 % | $ 107 M | USA |